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article
Prevalence of Triple-Negative Breast
Cancer in India: Systematic Review and
Meta-Analysis
abstract
Purpose There is considerable variation in prevalence rates of triple-negative breast cancer (TNBC)
reported by various studies from India. We performed a systematic review and literature-based meta-
analysis of these studies.
Methods We searched databases of Medline, Scopus, EMBASE, and Web of Science for studies that
reported on the prevalence of TNBC in India that were published between January 1, 1999, and December
31, 2015. We extracted relevant information from each study by using a standardized form. We pooled
study-specific estimates by using random-effects meta-analysis to provide summary estimates. We ex-
plored sources of heterogeneity by using subgroup analyses and metaregression.
Results Data were obtained from 17 studies that involved 7,237 patients with breast cancer. Overall
combined prevalence of TNBC was 31% (95% CI, 27% to 35%). There was substantial heterogeneity
across the studies (I2 of 91% [95% CI, 88% to 94%]; P < .001) that was not explained by available study
level characteristics, including study location, definition of human epidermal growth factor receptor 2 or
estrogen receptor, mean age of participants, proportion of patients with premenopausal cancer, grade 3
disease, or tumor size > 5 cm. Overall combined prevalence of hormone receptor–positive and human
epidermal growth factor receptor 2–positive breast cancer was 48% (95% CI, 42% to 54%) and 27%
(95% CI, 24% to 31%), respectively. There was no evidence of publication bias.
Conclusion Prevalence of TNBC in India is considerably higher compared with that seen in Western
populations. Asmany as as one in threewomenwith breast cancer could have triple-negative disease. This
finding has significant clinical relevance as it may contribute to poor outcomes in patients with breast
cancer in India. Additional research is needed to understand the determinants of TNBC in India.
J Glob Oncol 2. © 2016 by American Society of Clinical Oncology Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Breast cancer is a heterogeneous disease with
different biologic subtypes that are recognized
by gene expression profiling studies. Clinically,
these subtypes are characterized on the basis
of expression of estrogen receptor (ER), pro-
gesterone receptor (PR), and human epider-
mal growth factor receptor 2 (HER2). Triple-
negative breast cancer (TNBC) is an aggressive
subtype that is defined by lack of expression of
ER and PR as well as absence of overexpressed
or amplified HER2.1 TNBC accounts for approx-
imately 12% to 17% of all invasive breast cancers
in Western populations.1 TNBC occurs more fre-
quently in younger women and is associated with
higher histologic grade and more advanced
disease.1,2 InNorthAmerica, it ismore frequently
seen in women of African American ethnicity
compared with other ethnic groups.2-5
Breast cancer is the most common cancer in
India.6 For example, in 2012, it is estimated
that approximately 145,000 new patients were
diagnosed with breast cancer in India, and
nearly 70,000 women died of the disease.7
Age-standardized 5-year breast cancer survival
for Indian women diagnosed with breast cancer
is 60% compared with . 80% in Western coun-
tries.8Whereasbreast cancer incidenceseems to
be increasing in the country, epidemiology of the
disease is inadequately studied.9 Prevalence of
TNBC in India is reported to be higher than that
observed inWestern populations; however, there
is considerable variation in prevalence rates re-
ported by studies from the region. It is important
to obtain a reliable summary estimate of the
prevalence of TNBC in India to address the
growing burden of breast cancer in the country.
Hence, we conducted a systematic review and
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literature-based meta-analysis of studies that
reported on the prevalence of TNBC in India.
METHODS
Search Strategy
Studies that reported on the prevalence of TNBC
in India that were published between January 1,
1999, andDecember 31, 2015, were identified by
using Medline, Scopus, EMBASE, and Web of
Science databases (performed by G.S.S. and
H.P.). Preferred Reporting Items for Systematic
Reviews and Meta-Analyses guidelines were fol-
lowed for article search and reporting. Computer-
based search used combinations of the following
medical subject headings and keywords: triple
negative, breast cancer, and India.
Study Eligibility
We included studies in the meta-analysis if the
following criteria were met: provided data on pa-
tients with breast cancer in India and described
prevalence of triple-negative tumor subtype in the
study population. We excluded studies that were
comprised of patients with inflammatory breast
cancer.
Data Extraction
Two investigators (G.S.S. andA.M.) independently
screened all identified titles and abstracts from
the search results. We scanned the reference lists
of articles for additional articles. Full texts of
screened articles were reviewed by G.S.S. and
A.M. for inclusion criteria. Disagreements were
resolved by consensus. Study selection process
and flow diagram for identifying studies is detailed
inFigure1.Weextracted relevant information from
each study by using a standardized form, which
wasdesignedbefore implementationof the search
strategy. The following information was extracted
fromeacharticle byG.S.S. andA.M.: studydesign,
region, publication year, study year, mean age,
stage and grade distribution, receptor status, pro-
portionof patientswithductal histology, proportion
of patients with axillary lymph node involvement,
proportion of patients who were premenopausal,
and method of ER, PR, and HER2 assessment.
Definitions of ER, PR, and HER2
Level of ER is expressed as a product of the
percentage of epithelial cells stained and intensity
of staining through immunohistochemistry (IHC).
Historically, the cutoff value of ER-positive disease
was defined as nuclear staining of >10% of the
epithelial component of the tumor; however, in
2010ASCO lowered the IHCcutoff for determining
ER-positive status from the previous value of 10%
to 1% of stained cells.10 This was based on the
finding that even tumors weakly staining in 1%
to 10% of cells demonstrated objective clinical
benefit fromtreatmentwith tamoxifen.11Weextract-
eddata ondefinitions of ERandPRpositivity (>1%
or > 10% or not reported).
With regard to HER2 testing, ASCO released an
algorithm that defined positive, equivocal, and
negative values for both HER2 protein expression
and gene amplification. A positive HER2 result is
IHC staining of 3+ (uniform, intense membrane
staining of . 30% of invasive tumor cells), a
fluorescent in situ hybridization (FISH) result of
more than six HER2 gene copies per nucleus, or a
FISH ratio (HER2 gene signals to chromosome 17
signals) of more than 2.2. A negative result is an
IHC staining of 0 or 1+, a FISH result of fewer than
4.0HER2 gene copies per nucleus, or a FISH ratio
of less than 1.8.12 Equivocal results (IHC staining
of 2+) require additional testing for final classifi-
cation. We extracted data on HER2 assessment
method; studies that considered an IHC score of
2+ and 3+ as positive for HER2, studies that con-
sidered an IHC score of 3+ alone as positive for
HER2, studies that used FISH test in patients who
had 2+ score by IHC, and studies that did not
disclose the method of checking HER2 status.
Only studies that reported on all three receptors
(ER, PR, HER2) or those that reported on the
proportion of TNBC were included in analyses.
In some studies, more patients had data on ER or
PR status than on HER2. Hence, in those studies,
denominators were changed accordingly to pro-
vide an accurate assessment of the prevalence of
hormone receptor (HR)–positive disease (defined
as ER-positive and/or PR-positive), HER2-positive
disease, or TNBC.
Assessment of Study Quality
We used STROBE statement guidelines to assess
quality of selected studies.13 One point each was
given if the study described the setting and study
participants, reported descriptive data, provided
detailed outcome data, and discussed limitations,
for a maximum score of 5 and a minimum of zero.
We performed subgroup analysis stratified by
study quality score of > 4 versus , 4.
Statistical Analysis
Standard errors for study-specific prevalence es-
timates were determined from the point estimate
and appropriate denominators, assuming a bino-
mial distribution. To obtain an overall summary
estimate of prevalence across studies, we pooled
413 Volume 2, Issue 6, December 2016 ascopubs.org/journal/jgo JGO – Journal of Global Oncology
study-specific estimates by using a random-effects
model meta-analysis. We also performed a fixed-
effect model meta-analysis for comparison.
Between-study heterogeneity was quantified by
using I2 statistics. The I2 statistic estimates percent-
age of total variation across studies that are the
result of true between-studydifferences rather than
chance. We explored sources of heterogeneity by
using subgroup analyses and metaregression. We
assessed publication bias by using funnel plot sym-
metry and Egger regression intercept. All analyses
were performed using STATA software (v13; STATA,
College Station, TX; Computing Resource Center,
Santa Monica, CA). Statistical tests were two-sided,
and P , .05 was considered statistically significant.
RESULTS
Study Characteristics
Seventeen cross-sectional studies that involving
7,237 patients with breast cancer were included
in this review (Table 1).14-30 Mean age of patients
ranged from 43 to 55 years across studies, with a
weighted average of age 50 years. Proportion of
patients who were premenopausal ranged from
27%to67%across studies,withaweightedaverage
of 41%. Proportion of patients with grade 3 disease
rangedfrom16%to75%,withaweightedaverageof
57%; corresponding figures for patients with tumor
size . 5 cm were 3% to 65% (weighted average,
24%) and those for patients with positive axillary
lymph nodes were 39% to 90% (weighted average,
57%). Prevalence estimates of HR-positive disease,
HER2-positive disease, and TNBC in each of the
included studies are reported in Table 1.
Prevalence of TNBC
Overall combined prevalence of TNBC in the
random-effects model meta-analysis was 31%
(95% CI, 27% to 35%). Pooled estimate from the
fixed-effect model meta-analyses was comparable
(Fig 2). There was substantial heterogeneity across
the studies (I2 of 91.2% [95% CI, 88% to 94%];
P , .001). Sources of heterogeneity were explored
by several study-level characteristics, asdescribed in
Prevalence of TNBC by Study-level Characteristics.
Overall combined prevalence of HR-positive breast
cancer was 48% (95% CI, 42% to 54%; Fig 3), and
overallcombinedprevalenceofHER2-positivebreast
cancer was 27% (95% CI, 24% to 31%; Fig 4).
Prevalence of TNBC by Study-Level
Characteristics
In an attempt to explain heterogeneity, we per-
formed subgroup analysis and metaregression by
using several study-level characteristics (Fig 5).
Meta-analysis included four studies each from the
north, east, andwest of the country and five studies
Records identified via database search   (N = 242)
EMBASE (n = 87)
PubMed (n = 40)
Scopus (n = 77)
Web of Science (n = 38)
Unique articles screened (title and abstract)
by inclusion criteria (n = 129)  
Studies retrieved for detailed evaluation (n = 55)  
Duplicates removed (n = 113)  
Studies excluded on the basis of inclusion
criteria (n = 74)   
Further exclusions on the basis of full text review
Only subgroups included (n = 4)
Retracted (n = 1)
Conference presentations with no
full text available
(n = 33)
Studies included in the systematic review
and meta-analysis (all cross-sectional; n = 17)
Fig 1 –
Flow diagram for identifying
studies for assessment of
prevalence of triple-
negative breast cancer in
India.
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from the south. We found no significant difference
in prevalence of TNBC by region. Overall preva-
lence of TNBC in the north, south, east, andwest of
the country was 28%, 34%, 30%, and 31%, respec-
tively. Heterogeneity in overall prevalence of TNBC
was not explained by other available study-level char-
acteristics, such as mean age of participants or
proportion of patients who were premenopausal,
had grade 3 disease, or had tumor size . 5 cm.
Definition of ER, PR, and HER2
Definition of HR and HER2 was variable across
studies (Table 1). Nine studies defined HR-
Fixed Effect
Random Effects
Nandi 2014 E 135
Verma 2011 N 100
Sen 2012 E 72
Akhtar 2015 W 85
Rao 2013 S 126
Singh 2014 W 82
Zubeda 2013 S 300
Patnayak 2015 S 352
Nabi 2015 N 180
Ambroise 2011 S 321
Study
Pub.
Year Region No.
Mane 2015 W 521
Jana 2014 E 242
Lakshmaiah 2014 S 322
Doval 2015 N 1,284
Nigam 2014 N 142
Sharma 2014 E 972
Ghosh 2011 W 1,922
0.29 (0.28 to 0.30)
0.31 (0.27 to 0.35) 100.00
0.13 (0.08 to 0.19) 6.07
0.17 (0.10 to 0.24) 5.57
0.28 (0.17 to 0.38) 4.63
0.44 (0.33 to 0.54) 4.57
0.50 (0.41 to 0.59) 5.14
0.34 (0.24 to 0.44) 4.65
0.46 (0.40 to 0.52) 6.10
0.23 (0.18 to 0.27) 6.45
0.34 (0.27 to 0.41) 5.71
0.25 (0.20 to 0.30) 6.35
P  (95% CI) % Weight
0.25 (0.22 to 0.29) 6.60
0.47 (0.40 to 0.53) 5.91
0.26 (0.21 to 0.31) 6.34
0.24 (0.21 to 0.26) 6.87
0.39 (0.31 to 0.47) 5.36
0.32 (0.29 to 0.35) 6.77
0.30 (0.28 to 0.32) 6.92
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Prevalence (95% CI)
I2, 91.2%; P < .001  
Random Effects 0.48 (0.42 to 0.54)
Mane 2015 W 521 0.58 (0.54 to 0.63)
Fixed Effect 0.50 (0.49 to 0.51)
Rao 2013 S 126 0.37 (0.28 to 0.45)
Verma 2011 N 100 0.55 (0.45 to 0.65)
Nandi 2014 E 135 0.64 (0.56 to 0.72)
Jana 2014 E 242 0.30 (0.24 to 0.36)
Study
Pub.
Year Region No. P (95% CI)
Ambroise 2011 S 321 0.59 (0.54 to 0.64)
Sharma 2014 E 972 0.40 (0.37 to 0.43)
Ghosh 2011 W 1,922 0.51 (0.49 to 0.53)
Patnayak 2015 S 352 0.48 (0.43 to 0.53)
Singh 2014 W 82 0.45 (0.35 to 0.54)
Nabi 2015 N 180 0.48 (0.40 to 0.55)
Doval 2015 N 1,284 0.62 (0.60 to 0.65)
Sen 2012 E 72 0.36 (0.25 to 0.47)
Zubeda 2013 S 300 0.27 (0.22 to 0.32)
Nigam 2014 N 142 0.61 (0.53 to 0.69)
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Prevalence (95% CI)
I2, 95.5%; P < .001
Fig 2 –
Prevalence of triple-
negative breast cancer
across 17 studies in India.
E, east; N, north; S, south;
W, west.
Fig 3 –
Prevalence of hormone
receptor–positive breast
cancer across 17 studies in
India. E, east; N, north; S,
south; W, west.
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positive as ER and PR > 1% and four studies
defined HR-positive as ER and PR > 10%,
whereas four studies did not describe the defini-
tion of HR. Nine studies defined HER2-positive
status as only 3+ by IHC (Doval et al17 used FISH
test to classify equivocal cases and is therefore in-
cluded in the 3+ group) and five studies included
2+ as positive, whereas three studies did not de-
scribe the definition of HER2. We did not find
significant difference in pooled estimates sub-
grouped by different definitions for HR andHER2
(Fig 5).
Study Quality
One study scored the maximum score of 5, 11
studies scored 4, four studies scored 3, and one
study scored 2 on assessment of study quality.
Lower quality studies (study quality score , 4)
had a tendency to report higher prevalence of
TNBC compared with higher quality studies
(score > 4); 38% [95% CI, 27% to 48%] versus
29% [95% CI, 25% to 33%], respectively, al-
though confidence intervals overlap (P = .12;
Fig 5).
Assessment of Publication Bias
There was no evidence of publication bias by vi-
sual inspection of funnel plot or Egger test for bias
(P = .24; Appendix Fig A1). Furthermore, pooled
estimate fromlarger-sizedstudies (N>250),which
are less likely to be subjected to publication bias,
with that fromsmaller-sizedstudies (N,250)were
comparable (29% [95% CI, 25% to 32%] versus
34% [95% CI, 25% to 43%]; P = .34; Fig 4).
Sensitivity Analysis
Rao et al28 described a low prevalence of HER2-
positive disease (2.4%; n = 126). Prevalence of
TNBC in this study was 50%. Such a low rate of
HER2-positive diseasehasnot been reported from
India or elsewhere; however, a sensitivity analysis
performed after omitting data from the study yield-
ed results that were similar to the main analyses.
DISCUSSION
To our knowledge, this systematic review and
meta-analysis of 17 cross-sectional studies that
involved 7,237 patients with breast cancer is the
most comprehensive analysis on prevalence of
TNBC in India. Prevalence of TNBC in India
ranged from 27% to 35% across studies, with a
summary estimate of 31%. This is comparable to
the prevalence seen in African American women
and is more than twice the rate seen in white
women.5,31-34 Our study also found a higher prev-
alence of premenopausal breast cancer, grade 3
disease, and larger tumor size, all of which are
associated with triple-negative disease.1-3 Be-
cause TNBC is known to be more aggressive than
other breast cancer subtypes, higher prevalence
Study
Pub.
Year Region No.
Random Effects 0.27 (0.24 to 0.31)
FixedEffect 0.23 (0.22 to 0.24)
P (95% CI)
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Prevalence (95% CI)
I2, 88.7%; P < .001
Patnayak 2015 S 352 0.33 (0.28 to 0.38)
Mane 2015 W 521 0.31 (0.27 to 0.35)
Singh 2014 W 82 0.34 (0.24 to 0.44)
Jana 2014 E 242 0.27 (0.22 to 0.33)
Ambroise 2011 S 321 0.27 (0.22 to 0.32)
Nabi 2015 N 180 0.20 (0.14 to 0.26)
Doval 2015 N 1,284 0.23 (0.21 to 0.25)
Rao 2013 S 126 0.24 (0.21 to 0.26)
Ghosh 2011 W 1,922 0.17 (0.16 to 0.19)
Nandi 2014 E 135 0.33 (0.25 to 0.41)
Verma 2011 N 100 0.36 (0.27 to 0.45)
Zubeda 2013 S 300 0.36 (0.30 to 0.41)
Sharma 2014 E 972 0.22 (0.19 to 0.25)
Sen 2012 E 72 0.36 (0.25 to 0.47)
Nigam 2014 N 142 0.26 (0.19 to 0.33)
Fig 4 –
Prevalence of human
epidermal growth factor
receptor 2–positive breast
cancer across 17 studies in
India. E, east; N, north; S,
south; W, west.
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of TNBC could be a contributing factor to the high
fatality rate of patients with breast cancer in India.
We explored sources of heterogeneity through
subgroup analyses by using study-level charac-
teristics that are known to be associated with a
higher prevalence of TNBC, but results were not
statistically significant.Wealsoanalyzeddataonthe
basisof study locationand foundsimilarprevalence
rates for TNBC in all four regions in India. We also
found that differences in definitions of HR and
HER2 positivity did not influence study results.
One limitation of the present meta-analysis is
the presence of substantial heterogeneity across
the contributing studies that is unexplained by
available study-level characteristics; however,
similarity of findings from pooled estimates from
random-effects and fixed-effect models is reassur-
ing. Furthermore, pooled estimates from the small-
and larger-sized studies were comparable. India is
a vast country with significant variations in linguis-
tic, geographic, dietary, cultural, and health care–
associated practices; therefore, one can postulate
the presence of considerable inherent heterogene-
ity at state level that was not captured by regional
compartmentalization. Second, we did not incorpo-
rate quality scores into meta-analysis weights. An
analysis by study quality suggested a higher preva-
lence of TNBC in lower-quality studies; however,
difference in prevalence rates by study quality was
not statistically significant. Third, the contributing
study results are subjected to local laboratory stan-
dards and practices. Fourth, primary data are ob-
tained from studies that were conducted at various
tertiary-level hospitals, which could result in an in-
herent selection bias as a result of the possibility that
patients who havemore advanced disease could be
selectively referred to such institutions. However,
most cancer care in India occurs in tertiary-level
institutions, and, therefore, we do not think the ac-
tual prevalence rate will be significantly different
from that identified in our meta-analysis. Finally,
several potential risk factors, such as obesity, parity,
andsocioeconomic factors, havenotbeendescribed
in the studies that are included in this meta-analysis.
Multiple factors may account for higher preva-
lence of TNBC reported by studies conducted
among Indian patients with breast cancer. The
early ageof onset of breast cancer; lifestyle factors,
such as diet and obesity; reproductive factors,
such as multiparity; socioeconomic status; and
screening behaviors may be hypothesized as
probable etiology.2,3 Another important factor
could be a potential genetic susceptibility of In-
dians to TNBC. More focused research into these
factors will help clarify underlying determinants of
TNBC in India. A first step in this direction would
Subgroup
No. of
Studies
No. of
Patients 
P (95% CI) P
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Prevalence (95% CI)
Region
East 4 461 0.30 (0.17 to 0.43) .90
North 4 440 0.28 (0.20 to 0.37) .
South 5 446 0.34 (0.24 to 0.43) .
West 4 793 0.31 (0.26 to 0.36) .
Study size
< 250 9 414 0.34 (0.25 to 0.43) .34
≥ 250 8 1,726 0.29 (0.25 to 0.32) .
ER  ≥ 1% considered positive
No 4 371 0.31 (0.21 to 0.41) .93
Yes 9 1,554 0.30 (0.26 to 0.34) .
Not reported 4 215 0.33 (0.16 to 0.50) .
HER2 3+ considered positive
No 5 451 0.29 (0.21 to 0.37) .88
.Yes 9 1,530 0.32 (0.27 to 0.36)
Not reported 3 159 0.31 (0.09 to 0.54) .
Study quality
< 4 5 454 0.38 (0.27 to 0.48) .12
≥ 4 12 1,686 0.29 (0.25 to 0.33) .
Fig 5 –
Prevalence of triple
negative breast cancer by
various study
characteristics. ER,
estrogen receptor; HER2,
human epidermal growth
factor receptor 2.
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be to institute a prospectively managed,
population-based database of patients with breast
cancer, along with reliable histopathologic testing.
In conclusion, this systematic review and meta-
analysis demonstrated a high prevalence rate of
TNBC in India. Further research to identify the
determinants of such a high prevalence of TNBC
is warranted as they may have implications for
addressing the burden of breast cancer mortality
in India.
DOI: 10.1200/JGO.2016.005397
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APPENDIX
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Fig A1 –
Funnel plot with pseudo
95% CIs. TNBC, triple-
negative breast cancer.
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